Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus casei ŁOCK 0918 + lactobacillus rhamnosus ŁOCK 0900 + lactobacillus rhamnosus ŁOCK 0908
- Development stage
- Unknown
- Lead developer
- IBSS Biomed
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This is a probiotic mixture containing three bacterial strains: Lactobacillus casei ŁOCK 0918, Lactobacillus rhamnosus ŁOCK 0900, and Lactobacillus rhamnosus ŁOCK 0908. The mixture has been studied for its therapeutic benefits in children with atopic dermatitis and cow's milk protein allergy. Clinical trials have shown that this probiotic combination can significantly improve symptoms of atopic dermatitis, particularly in allergen-sensitized patients. The mixture is typically administered in specific proportions: 50% Lactobacillus casei ŁOCK 0918, 25% Lactobacillus rhamnosus ŁOCK 0908, and 25% Lactobacillus rhamnosus ŁOCK 0900.
- Brand names
- Latopic
- Other names
- ŁOCK probiotic mixtureprobiotic ŁOCK strains
02
Targets
TLR2 (Toll-like Receptor 2)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)
Beyond the preview
Go deeper on lactobacillus casei ŁOCK 0918 + lactobacillus rhamnosus ŁOCK 0900 + lactobacillus rhamnosus ŁOCK 0908.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus casei ŁOCK 0918 + lactobacillus rhamnosus ŁOCK 0900 + lactobacillus rhamnosus ŁOCK 0908.